Studies indicate that QRT treatment decreases NF-κB activity in various cancer types, including breast and prostate cancers, thereby sensitizing tumour cells to apoptosis and limiting inflammation-driven tumour growth and by modulating NF-κB signalling, QRT not only induces apoptosis but also creates a less favorable microenvironment for tumour growth [130]. The gene discussed is NFKB1; the disease is Familial prostate cancer.